C4 Therapeutics, Inc. Research and Development Expense
C4 Therapeutics, Inc. (CCCC) reported Research and Development Expense of $24.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- C4 Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $24.47M, a 6.59% decline year-over-year.
- C4 Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $24.61M, a 9.11% decline year-over-year.
- C4 Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $24.98M, a 23.16% decline year-over-year.
- C4 Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $25.99M, a 18.37% decline year-over-year.
- C4 Therapeutics, Inc. research and development expense for fiscal 2025 was $104.24M, a 5.78% decline from fiscal 2024.
- C4 Therapeutics, Inc. research and development expense for fiscal 2024 was $110.64M, a 6.01% decline from fiscal 2023.
- C4 Therapeutics, Inc. research and development expense for fiscal 2023 was $117.71M, a 0.11% decline from fiscal 2022.
- C4 Therapeutics, Inc. research and development expense for fiscal 2022 was $117.84M, a 24.48% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.47M 10-Q · filed 2026-08-11 | $49.08M 10-Q · filed 2026-08-11 | $74.06M derived: sum of 3 quarters · filed 2026-08-11 | $100.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $24.61M 10-Q · filed 2026-05-12 | $49.59M derived: sum of 2 quarters · filed 2026-05-12 | $75.58M derived: sum of 3 quarters · filed 2026-05-12 | $101.77M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $24.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $50.97M derived: sum of 2 quarters · filed 2026-02-26 | $77.17M derived: sum of 3 quarters · filed 2026-08-11 | $104.24M 10-K · filed 2026-02-26 |
| 2025-09-30 | $25.99M 10-Q · filed 2025-11-06 | $52.19M derived: sum of 2 quarters · filed 2026-08-11 | $79.26M 10-Q · filed 2025-11-06 | $111.77M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $26.20M 10-Q · filed 2026-08-11 | $53.27M 10-Q · filed 2026-08-11 | $85.78M derived: sum of 3 quarters · filed 2026-08-11 | $117.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $27.07M 10-Q · filed 2026-05-12 | $59.59M derived: sum of 2 quarters · filed 2026-05-12 | $91.42M derived: sum of 3 quarters · filed 2026-05-12 | $115.18M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $32.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $64.35M derived: sum of 2 quarters · filed 2026-02-26 | $88.10M derived: sum of 3 quarters · filed 2026-02-26 | $110.64M 10-K · filed 2026-02-26 |
| 2024-09-30 | $31.84M 10-Q · filed 2025-11-06 | $55.59M derived: sum of 2 quarters · filed 2025-11-06 | $78.12M 10-Q · filed 2025-11-06 | $108.52M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $23.75M 10-Q · filed 2025-08-07 | $46.29M 10-Q · filed 2025-08-07 | $76.68M derived: sum of 3 quarters · filed 2025-08-07 | $105.02M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $22.53M 10-Q · filed 2025-05-07 | $52.92M derived: sum of 2 quarters · filed 2025-05-07 | $81.27M derived: sum of 3 quarters · filed 2025-05-07 | $111.20M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $30.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $58.74M derived: sum of 2 quarters · filed 2025-02-27 | $88.66M derived: sum of 3 quarters · filed 2025-02-27 | $117.71M 10-K · filed 2025-02-27 |
| 2023-09-30 | $28.35M 10-Q · filed 2024-10-31 | $58.27M derived: sum of 2 quarters · filed 2024-10-31 | $87.31M 10-Q · filed 2024-10-31 | $117.97M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $29.93M 10-Q · filed 2024-08-01 | $58.97M 10-Q · filed 2024-08-01 | $89.62M derived: sum of 3 quarters · filed 2024-08-01 | $119.28M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $29.04M 10-Q · filed 2024-05-08 | $59.69M derived: sum of 2 quarters · filed 2024-05-08 | $89.36M derived: sum of 3 quarters · filed 2024-05-08 | $120.68M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $30.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $60.31M derived: sum of 2 quarters · filed 2024-02-22 | $91.64M derived: sum of 3 quarters · filed 2024-02-22 | $117.84M 10-K · filed 2024-02-22 |
| 2022-09-30 | $29.66M 10-Q · filed 2023-11-01 | $60.99M derived: sum of 2 quarters · filed 2023-11-01 | $87.19M 10-Q · filed 2023-11-01 | $113.74M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $31.32M 10-Q · filed 2023-08-08 | $57.53M 10-Q · filed 2023-08-08 | $84.08M derived: sum of 3 quarters · filed 2023-08-08 | $108.38M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $26.20M 10-Q · filed 2023-05-04 | $52.75M derived: sum of 2 quarters · filed 2023-05-04 | $77.06M derived: sum of 3 quarters · filed 2023-05-04 | $100.34M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $26.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $50.85M derived: sum of 2 quarters · filed 2023-02-23 | $74.14M derived: sum of 3 quarters · filed 2023-02-23 | $94.67M 10-K · filed 2023-02-23 |
| 2021-09-30 | $24.30M 10-Q · filed 2022-11-03 | $47.59M derived: sum of 2 quarters · filed 2022-11-03 | $68.11M 10-Q · filed 2022-11-03 | $88.55M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $23.29M 10-Q · filed 2022-08-04 | $43.81M 10-Q · filed 2022-08-04 | $64.25M derived: sum of 3 quarters · filed 2022-08-04 | $88.18M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $20.53M 10-Q · filed 2022-05-05 | $40.96M derived: sum of 2 quarters · filed 2022-05-05 | $64.89M derived: sum of 3 quarters · filed 2022-05-05 | $82.65M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $20.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $44.37M derived: sum of 2 quarters · filed 2022-02-24 | $62.13M derived: sum of 3 quarters · filed 2022-02-24 | $78.44M 10-K · filed 2022-02-24 |
| 2020-09-30 | $23.93M 10-Q · filed 2021-11-10 | $41.70M derived: sum of 2 quarters · filed 2021-11-10 | $58.01M 10-Q · filed 2021-11-10 | $74.02M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $17.76M 10-Q · filed 2021-08-11 | $34.07M 10-Q · filed 2021-08-11 | $50.09M derived: sum of 3 quarters · filed 2022-02-24 | $63.04M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $16.31M 10-Q · filed 2021-05-13 | $32.33M derived: sum of 2 quarters · filed 2022-02-24 | $45.28M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $16.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $28.96M derived: sum of 2 quarters · filed 2022-02-24 | $48.06M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $12.95M 10-Q · filed 2020-11-12 | $32.04M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |